The International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) aims to be a supportive decision-making tool by providing an accepted practical, transparent and standardised approach for the management of anticancer drug dosing in kidney dysfunction based on current evidence and clinical consensus.
Viewing this on mobile? Tell us what you thought. Complete the survey.
Understand the purpose of the ADDIKD guideline, methods of assessing kidney function in cancer patients, why eGFR (via CKD-EPI) is the preferred method of estimating kidney function, and kidney function categories for dosing and monitoring.
Understand the ADDIKD recommendations for the dosing of carboplatin as this rapid learning works through an example using body surface area (BSA) adjusted eGFR in the Calvert formula to calculate a carboplatin dose.
For more in-depth information see the International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction on eviQ.